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ABSTRACT
Introduction The PiSZ genotype results in less severe
deﬁciency of alpha-1 antitrypsin (AAT) than PiZZ. Less is
known about phenotypic and prognostic features.
Methods We studied 699 PiZZ, 126 PiSZ and 316
PiMM patientsQ7 . All AAT deﬁciency (AATD) patients were
augmentation naive. PiSZ were compared with PiZZ
patients for clinical phenotype at baseline including CT
ﬁndings, smoke exposure, progression of lung disease
and survival. Similarly, PiSZ patients diagnosed as a
result of investigation for possible lung disease (lung
index cases) were compared with PiMM. Multivariable
analytical techniques and matching (PiSZ to PiZZ) were
employed to account for demographic differences.
Results Pack-years smoked and FEV1 exhibited a
negative correlation in PiSZ and ZZ patients (both
r=−0.43), with emphysema and COPD occurring more
commonly in PiZZ patients at <20 pack-year exposure.
In multivariable analyses, PiSZ patients were less likely to
have emphysema (p<0.01) and had better survival than
PiZZ (p=0.017), but lung function decline did not differ
signiﬁcantly. 42% of PiSZ patients had upper-zone-
dominant emphysema on CT scan. Analyses of AAT level
conﬁrmed a critical threshold at 11 μM, particularly with
regard to phenotypes classical of PiZZ AATD.
Signiﬁcant baseline differences suggested that PiSZ
had presented earlier to health services than PiMM.
Once this was accounted for, risk of emphysema did not
differ between PiSZ and PiMM although survival was
lower in PiMM patients (p<0.01).
Conclusions PiSZ patients are less susceptible to
cigarette smoke than PiZZ. The pattern of emphysema
may be similar at diagnosis to usual COPD.
Q6
INTRODUCTION
Alpha-1 antitrypsin deﬁciency (AATD) results from
several deﬁciency alleles, with severe deﬁciency
occurring in Z allele homozygotes (PiZZ), or car-
riers of null alleles leading to absence of AAT1 and
is associated with early-onset emphysema.2 The S
allele leads to a milder deﬁciency, and there has
been considerable debate about whether heterozy-
gous PiSZ patients are at increased risk of lung
disease, largely due to the confounding factor of
acquisition bias in some prior work. A
meta-analysis concluded that PiSZ patients exhibit
a risk of COPD over three times that of a normal
individual;3 however, this result was inﬂuenced by
one study showing a large increase in risk.4
Previous studies of PiSZ patients are summarised in
online supplementary table 1.
Epidemiological studies suggest that there are
>500 000 PiSZ individuals in Europe,5 who typic-
ally exhibit an AAT level less than half that of a
normal (PiMM) person.6 An interaction between
AAT and cigarette smoke exposure occurs in
murine models, where emphysema develops more
rapidly.7 This, together with the available epidemi-
ology, suggests that PiSZ patients should have a
lung disease risk lying between PiMM and PiZZ
patients, given the same level of smoke exposure.
Consistent with this, we have shown in a relatively
small cohort (n=63), matched for smoking status,
that PiSZ patients exhibit less severe lung disease
than PiZZ.8 Even low levels of smoke exposure
may be deleterious to lung function in PiZZ
patients; however, an important threshold may
occur at 20 pack-years, above which associations
between FEV1 and pack-years are less apparent.9
Whether this differs in PiSZ patients is unknown,
and little is known about their prognosis. We
sought to conﬁrm the pattern of lung disease exhib-
ited by PiSZ patients, explore the relationship
between cumulative smoke exposure, AAT level
and severity of disease, and compare prognosis
between PiSZ, PiZZ and PiMM patients.
Key messages
What is the key question?
▸ Are patients with the PiSZ genotype for alpha-1
antitrypsin deﬁciency (AATD) similar to classical
PiZZ AATD or to usual COPD?
What is the bottom line?
▸ Many PiSZ patients look phenotypically similar
to usual COPD at their ﬁrst assessment; the
interaction between their AAT level and smoke
exposure appears critical in determining
subsequent decline.
Why read on?
▸ Detailed phenotypic data, decline of lung
function and mortality analyses are presented
between PiSZ, PiZZ and PiMM, together with
an exploration of threshold levels of smoke
exposure in AATD and current knowledge
pertinent to diagnosing and managing AATD.
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METHODS
Subjects
The UK AATD registry (ADAPT) was established in 1996 and
has been described in detail elsewhere.10 Brieﬂy, patients
undergo annual lung physiology, biological sample collection
and clinical assessment. At enrolment most patients have a chest
CT scan; quantitative CT analysis was undertaken by density
mask analysis of 5 mm CT scan slices; voxel indices (VI) at
−910 (the proportion of lung voxels below −910 Hounsﬁeld
Units (HU)) and the ratio between the upper and lower zones
calculated.11 Lung function decline was determined on all
patients with ≥3 years’ follow-up; methods for calculation of
decline have been described in our previous work.12 All patients
with PiSZ and PiZZ genotypes were selected. Those diagnosed
due to investigation for symptoms/signs of lung disease were
termed lung index cases.
PiMM patients with usual COPD comprised all patients in
the West Midlands COPD cohort (WMCC; described in our
previous published work13) and all patients from the Chronic
Diseases Resource Centre (CDRC; a University of Birmingham
COPD patient registry, identiﬁed from local clinics). The CDRC
has superceded the WMCC and has assessment procedures
similar to the UK AATD registry. Data on CT density and
decline in lung function were not available for PiMM patients,
as referring centres used a variety of CT protocols, and had
either not been followed up for sufﬁcient time or had insufﬁ-
cient lung function data to calculate decline.
Statistical analysis
All analyses were carried out in SPSS (SPSS V.20; IBM, USA).
Univariable analyses compared PiSZ and PiZZ patients for
demographics, smoking status, index status, occupational expos-
ure (assessment methods described in our previous work12),
comorbidities, lung function, CT densitometry (where available)
survival and lung function decline. Analyses were performed
using χ2 tests for categorical variables and Mann–Whitney U
tests for continuous variables, substratifying by index status,
smoking status and presence of COPD for analyses pertaining to
decline. Co-variables for logistic, linear and Cox regression ana-
lyses were selected if p<0.1 in univariable analysis and no sig-
niﬁcant collinearity with another included variable. Prior
literature on inﬂuences on mortality14 and decline12 15 16 in
AATD were used to aid prioritisation of co-variables where
necessary. All results from the multivariable analysis are reported
as two-tailed; signiﬁcance was taken at p<0.05. Since there
were demographic differences between PiSZ and PiZZ patients,
for which subgroup analyses and statistical adjustment in regres-
sion analysis might be imperfect, an attempt at a matched ana-
lysis was also made (see online supplementary data). Within the
whole AATD group, the relationship of AAT level to clinical
phenotype and decline was conducted using similar techniques.
Finally, univariable analyses were undertaken comparing lung
index PiSZ and PiMM patients for demographics, smoking
status, clinical phenotype and survival. Results guided logistic
and linear regressions similar to the PiSZ versus PiZZ
comparisons.
RESULTS
Comparison of PiSZ and PiZZ patients
Table 1 shows patients’ characteristics and univariable analyses.
PiZZ patients were more likely to be lung index cases and ex
smokers, had higher rates of emphysema, bronchiectasis and
chronic bronchitis, worse lung function (in all parameters), lower
AAT levels and worse survival. Almost all (99.8%) PiZZ patients
and 11.3% PiSZ patients had AAT<11 μM. CT scans were avail-
able on 37 non-index and 64 index PiSZ patients (index vs non-
index characteristics; see online supplementary table 2). Smoking
appeared to be a greater inﬂuence on clinical phenotype than
PiSZ versus PiZZ genotype (smoke exposed vs never smokers’
characteristics; see online supplementary table 3).
Direct correlation between FEV1% predicted and pack-years
occurred up to a break point, which appeared similar to the
published 20 pack-year threshold in PiZZ patients, though pos-
sibly higher in PiSZ (ﬁgure 1A, B). The proportion of emphy-
sema and COPD cases occurring below 20 pack-years was
greater in PiZZ patients (ﬁgure 1C, D). There was no difference
in prevalence of common comorbidities (IHD, osteoporosis,
anxiety, depression), age, pack-years smoked or occupational
exposure risks (all p>0.2). Multivariable logistic regressions,
stratiﬁed for method of ascertainment of AATD, including
smoke exposure and age as covariates, showed that emphysema
was less common in lung index and family screened PiSZ
patients (OR 0.15 and 0.03; p=0.003 and <0.001, respect-
ively), while rates of chronic bronchitis and bronchiectasis were
similar between groups (all p>0.2). In linear regressions strati-
ﬁed for method of ascertainment of AATD and adjusting for
smoking status and age, lung index PiSZ patients had signiﬁ-
cantly better lung function compared with PiZZ (all parameters
shown in table 1, p<0.05), while non-index PiSZ patients were
better in most parameters (residual volume and total lung cap-
acity no difference, other parameters p<0.05). Matched ana-
lyses were no different (see online supplementary results).
Differences in emphysema between PiSZ and PiZZ patients
were more marked in the lower zones (ﬁgure 2); 42.9% of PiSZ
patients scanned had upper-zone-dominant emphysema com-
pared with 14.1% of PiZZ (both p<0.01).
Sufﬁcient physiological data to calculate decline were available
in 68 PiSZ and 514 PiZZ patients, with a mean of ﬁve measures
per PiZZ and four per PiSZ patient. 22.5% of PiZZ patients
had COPD with FEV1 <30% predicted (n=116), 33.5% had
FEV1 30–50% (n=172), 25% (n=129) had COPD with FEV1
>50% predicted and the remainder did not have COPD at the
start of the decline calculation period (n=97). In the PiSZ
patients, these ﬁgures were 11.3%, 8.1%, 17.7%, 29% and
33.9% (n=8, 5, 12, 20 and 23), respectively. Decline in FEV1
in some subgroups of interest is shown in table 2. Median
decline was greatest when baseline FEV1 was 50–80% predicted
(PiZZ −56.3 mL/year, PiSZ −65.3 mL/year, p=0.707). There
was no difference in annual decline of FEV1 or gas transfer
(DLCO Q8and KCO) %predicted when analysed as categories
(ﬁgure 3) or continuous variables. Regression analyses stratiﬁed
for smoking status, presence of COPD and index status, adjust-
ing for baseline lung function and age did not inﬂuence this
similarity (all p>0.18 for smoking status, p>0.33 for COPD,
p>0.77 for index status), nor did matching (see online supple-
mentary results). Cox regression analyses, including age,
smoking status, index status and baseline FEV1 as co-variables,
showed signiﬁcantly better survival in PiSZ patients (ﬁgure 4A).
We then explored the importance of AAT level with regard to
susceptibility to smoke, subsequent development of lung disease
and decline. When considered as a continuous variable, AAT
level had no signiﬁcant impact on logistic regressions seeking
associations of emphysema, chronic bronchitis and bronchiec-
tasis. However, a level of Q9≤11 μM associated with development
of emphysema (p<0.001), an UZ/LZVI Q10suggestive of lower-
zone-dominant disease (p<0.001) and chronic bronchitis
(p<0.001). There was a strong trend toward interaction between
AAT ≤11 μM and pack-years smoked with regard to risk of
2 Green CE, et al. Thorax 2015;0:1–7. doi:10.1136/thoraxjnl-2015-206906
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Table 1 Clinical characteristics of patients
Feature
PiZZ PiSZ PiSZ lung index cases PiMM p Value
n=699 n=126 N=64 N=316 PiSZ vs PiZZ PiSZ index vs PiMM
Male 404 (57.8) 71 (56.3) 38 (59.4) 182 (57.7) 0.717 0.810
Age 50.8 ((16.4 Q11) 53.5 ((20.0) 55.4 ((1.5) 68.4 ((13.6) 0.021 <0.001
Smoking status <0.001 0.004
Ex smoker 510 (73.0) 56 (44.4) 37 (57.8) 192 (60.0)
Never smoked 161 (23.0) 43 (34.1) 15 (23.4) 3 (0.9)
Current smoker 28 (4.0) 27 (21.4) 12 (18.8) 121 (39.0)
Pack-years smoked 13.5 ((23.5) 13.0 ((35.4) 26.2 ((3.0) 44.2 ((32.5) 0.402 <0.001
Reason for diagnosis – – 0.007 –
Lung disease 532 (76.2) 77 (61.0)
Family screening 118 (16.9) 38 (30.5)
Liver disease 11 (1.6) 1 (0.8)
Other reason 38 (5.4) 10 (7.9)
COPD 587 (84.0) 66 (52.4) 43 (67.2) 316 (100) <0.001 <0.001
Emphysema 528 (75.5) 46 (36.5) 35 (54.7) 257 (81.3) <0.001 <0.001
Chronic bronchitis 249 (35.6) 31 (24.6) 18 (28.1) 198 (62.8) 0.034 0.037
Bronchiectasis 189 (27.0) 22 (17.4) 11 (17.2) 96 (30.3) 0.041 <0.001
AAT level 4.0 ((2.1) 14.4 (4.4) 14.9 (3.7) – <0.001 –
FEV1pp 47.9(45.6) 94.5 (51.3) 76.5 (2.6) 46.4 (26.0) <0.001 <0.001
FEV1/FVC (%) 38.2 (26.4) 67.5 (37.5) 55.0 (2.7) 43.3 (20.0) <0.001 0.004
TLCpp 115.3 (21.9) 107.4 (18.3) 109.2 (1.9) 103.0 (20.2) <0.001 <0.001
RVpp 119.3 (54.9) 96.9 (46.3) 107.9 (4.6) 119.8 (53.8) <0.001 <0.001
DLCOpp 69.74(36.0) 86.3 (34.2) 76.5 (3.1) 48.6 (23.9) <0.001 <0.001
KCOpp 64.3 (28.8) 89.0 (29.5) 78.1 (3.0) 59.0 (29.6) <0.001 <0.001
Follow-up time (years) 10.4 (5.3) 7.0 (8.5) 7.8 (0.6) 3.2 (3.0) 0.021 <0.001
Deceased 172 (24.6) 10 (7.9) 7 (10.9) 91 (28.8) <0.001 0.003
Data are shown as n (%) or median (IQR). In PiSZ index cases, data are shown as mean (SE) due to normal distribution.
AAT, alpha-1 antitrypsin; DLCO, carbon monoxide diffusing capacity; KCO, carbon monoxide transfer coefficient; RV, residual volume; TLC, total lung capacity.
Figure 1 Relationship between pack-years smoked and lung function in alpha-1 antitrypsin deﬁciency. There was a linear relationship between
baseline FEV1 and pack-years up to a threshold of 30 pack-years in PiSZ patients, which then disappeared (A; r=−0.43 at <30, r=−0.02 at ≥30
pack-years). The relationship was similar in PiZZ patients, but with a lower pack-year threshold (B; r=−0.43 at <20, r=0.04 at ≥20 pack-years).
Illustrative smoothed regression lines are shown on the graphs. Both emphysema (C) and COPD (D) were more common at exposures <20
pack-years in PiZZ patients.
Green CE, et al. Thorax 2015;0:1–7. doi:10.1136/thoraxjnl-2015-206906 3
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chronic bronchitis (p=0.09), but not other phenotypes.
Furthermore, interaction between AAT level and pack-years
smoked was signiﬁcant in a multivariable general linear model
for FEV1 decline (one-tailed test p=0.026), whereas AAT level
alone and PiSZ*pack-years interaction were not (both one-tailed
p=0.150).
Comparison with usual COPD
The primary reason for inclusion of PiMM patients was to see
whether their phenotype was similar to PiSZ, hence univariable
analyses were restricted to PiSZ index cases, as this eliminated
ascertainment differences. Logistic regressions adjusting for age,
smoke exposure and baseline FEV1 (different in univariable
analyses; table 1) demonstrated that PiSZ patients had a similar
risk of emphysema (p=0.274) and bronchiectasis (p=0.344),
but lower risk of chronic bronchitis (OR 0.36 (0.18–0.72);
p=0.016). Cox regression conﬁrmed better survival in PiSZ
patients (ﬁgure 4B).
DISCUSSION
We have conﬁrmed that PiSZ patients have a lower risk of lung
disease and are less susceptible to effects of cigarette smoke
than PiZZ individuals, exhibiting a clinical phenotype, which is
in many cases similar to usual PiMM COPD. Interpreting the
prognostic data is more difﬁcult due to issues of power and
baseline differences between groups.
Pulmonary phenotype
This study is the largest to date on PiSZ AATD. In our earlier
study, lung function and CT scan appearances concurred with
those reported here; many PiSZ patients exhibited no emphy-
sema, and many who did had upper-zone-dominant disease.8
This agrees with data from an earlier, small, British PiSZ cohort17
and with much of the past PiSZ literature. The expected number
of UK PiSZ patients exceeds PiZZ,5 yet there are far fewer PiSZ
known to the registry. This may reﬂect ascertainment bias since
AAT testing possibly occurs more frequently in patients with
COPD exhibiting classical AATD lung disease (ie, lower-zone-
dominant emphysema). A missed diagnosis could have conse-
quences since there is speciﬁc treatment for AATD lung disease in
the form of AAT augmentation (available in the USA and many
European countries, albeit not yet in the UK), which undiagnosed
patients would not receive. Most international AATD guidelines
specify that their scope is PiZZ patients or those with a circulating
AAT level typical of PiZZ, and recommend the use of augmenta-
tion in the presence of emphysema and a speciﬁed level of
FEV1.18 19 This would exclude almost 90% of our PiSZ patients
on the basis of AAT level.6 The main effect of augmentation is on
progression of emphysema, best measured by CT densitometry,20
although effects on FEV1 decline have been reported in non-
randomised studies.21 Progression of emphysema on augmenta-
tion varies according to lung zone,11 hence augmentation might
beneﬁt PiSZ patients who exhibit lower-zone-dominant disease
and low AAT levels (equivalent to PiZZ). Our data examining the
threshold AAT level of 11 μM support this, although speciﬁc
studies in PiSZ patients would be required to determine this with
conﬁdence.
We also conﬁrmed that PiSZ patients are less susceptible to
smoke. A direct relationship between FEV1 and smoke exposure
occurred below 30 pack-years in PiSZ and 20 pack-years in
PiZZ patients. The reasons for this are discussed elsewhere,9
one of which is a ‘ﬂoor effect’, in which lung function has
dropped sufﬁciently by the threshold that in many patients
either no further decline occurs or they die. A smaller amount
of ‘resistant’ smokers is also seen, adding to the lack of correl-
ation at higher smoke exposures. While the data for the speciﬁc
threshold were weak, the proportion of PiSZ patients develop-
ing emphysema or COPD at exposures <20 pack-years was also
lower, supporting its existence. Moreover, the American NHLBI
cohort reported the importance of smoking in disease develop-
ment in PiSZ patients with AAT <11 μM, alongside less lung
function impairment than in PiZZ, thus supporting our data.22
A difference in the threshold at which smoke susceptibility
occurs between PiSZ and ZZ patients is consistent with current
understanding of AAT–neutrophil elastase (NE) interactions,
whereby the area of obligate damage is exponentially related to
AAT level, rising markedly at <11 μM,23 and therefore leading
to a critical area of lung damage more quickly in PiZZ.
Interestingly, among the PiSZ never smokers clinically signiﬁcant
Figure 2 Characteristics of emphysema in alpha-1 antitrypsin deﬁciency patients. (A) CT density (VI-910) in upper and lower zones was worse in
PiZZ with differences being marked in lower zone (p<0.01) and marginal in upper zone. Voxel index (VI) at −910 is the proportion of lung voxels
below −910 Hounsﬁeld Units (HU). (B) UZ/LZVI: Lower values demonstrate predominance of basal emphysema in PiZZ (p=0.001).
Table 2 FEV1 decline (mL/year) in PiSZ and PiZZ alpha-1
antitrypsin deficiency
Variable PiZZ PiSZ p Value
Current smoker −16.0 (−8.1 to −56.6) −59.6 (−16.8 to −79.4) 0.287
Ex smoker −37.0 (−10.0 to −76.1) −41.8 (−26.6 to −88.5) 0.155
Never smoker −41.6 (−3.4 to −77.7) −33.6 (−11.9 to −66.9) 0.542
COPD −38.2 (−9.2 to −76.1) −52.3 (−24.4 to −94.3) 0.818
No COPD −34.7 (−7.5 to −71.8) −35.1 (−13.6 to −67.8). 0.120
Lung index case −38.1 (−8.6 to −85.2) −41.8 (−19.7 to −85.4) 0.278
Non-lung index
case
−38.1 (−7.9 to −82.4) −36.5 (−14.2 to −67.7) 0.879
4 Green CE, et al. Thorax 2015;0:1–7. doi:10.1136/thoraxjnl-2015-206906
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emphysema was uncommon, implying that in the absence of
smoke it is not a risk factor—similar to PiMZ.24
We then compared PiSZ and MM patients to test our hypoth-
esis that there would be a degree of phenotypic overlap,
perhaps sufﬁcient to make the two groups indistinguishable,
thus accounting for missed diagnoses (relative to PiZZ). The
potential impact of individuals with AATD diagnosed through
family screening, who were not present in the usual COPD
Figure 3 Decline in lung function in alpha-1 antitrypsin deﬁciency. The graphs show the proportion of patients with lung function that did not
deteriorate, decreased by up to 1% of predicted (ie, fell from 50% predicted in year 1 to ≥49% predicted in year 2), between 1% and 2% predicted
and >2% predicted per year. (A) FEV1, (B) DCLO and (C) carbon monoxide transfer coefﬁcient (KCO). There were no differences in the proportion of
patients in each group (FEV1, p=0.67; DCLO, p=0.22; KCO=0.60).
Figure 4 Cox regression demonstrating survival. (A) PiSZ (dashed line) versus PiZZ (solid line); analysis adjusted for baseline FEV1, age, index
status and smoking. PiSZ patients had better survival (p=0.017; log rank). (B) Lung index PiSZ (dashed line) versus PiMM (solid line); analysis
adjusted for baseline FEV1, age and pack-years smoked. PiSZ patients had better survival (p<0.001; log rank).
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group, meant that statistical analyses compared lung index cases
—risks of emphysema were similar, after adjustment for smoke
exposure and age. This is consistent with PiSZ patients outside
our cohorts being diagnosed less readily.
Prognosis
Our data implied that disease progression in PiSZ patients
might be similar to PiZZ. This result was unexpected; PiSZ
patients were generally better at baseline, which we have shown
to relate to more rapid FEV1 decline,10 16 while PiZZ patients
were worse, which we have shown to relate to more rapid gas
transfer decline.10 16 We therefore expected differences to occur
in raw decline values, which would be less apparent after adjust-
ment for baseline lung function and smoke exposure. However,
raw values were similar and remained so regardless of the
method by which we attempted to control for baseline differ-
ences. This may be explicable if AAT level is more critical than
PiSZ genotype; consistent with this our data implied that AAT
level, rather than PiSZ genotype, interacted with smoke expos-
ure in the lung function decline models. AAT level does vary
among PiSZ patients, presumably due to modifying effects of
other genes or environmental factors, which is one reason why
current guidelines for treatment take this feature into account.
No prior PiSZ studies have reported FEV1 decline (see online
supplementary table 1); however, there are data available on
decline in PiZZ, where loss of FEV1 was generally 60–80 mL/
year.15 25–28 This is somewhat higher than the median in our
PiZZ patients. Notably, the largest prior PiZZ study25 (see
online supplementary table 4) exhibited both starting FEV1
(49% predicted) and FEV1 decline similar to many of our PiZZ
patients (54 mL/year vs 56.3 mL/year in our FEV1 50–80% sub-
group). Our lower median is explicable by cohort character-
istics. There are two groups in whom FEV1 decline is known to
be lower—those with FEV1 <30% predicted10 or with no
emphysema on their CT, who comprise 22.5% and 26.3% of
our AATD cohort, respectively. High rates of patients with
FEV1 <30% account for the low decline seen in our PiZZ
current smokers, whose minimum FEV1 was just 12%, thus had
no lung function to lose. Furthermore, our method of determin-
ing decline may be more accurate compared with previous
studies, which calculated decline from just two data points,25 or
over only 2 years in some patients.28 Thus we feel our decline
data are accurate and comparable to other published data, once
our cohorts’ characteristics are taken into account. However, we
acknowledge that a survivor bias, and relatively small numbers,
in the decline analyses may have limited power to detect true
differences between PiSZ and ZZ patients. While we tried to
adjust for baseline differences in lung function (eg,11.3% of
patients had FEV1<30% predicted in the PiSZ decline group
compared with 22.5% of the PiZZ), statistical adjustment could
have been incapable of fully accounting for differences. To over-
come this, we attempted matching (see online supplementary
data), which again showed no difference in decline. However,
high smoke exposures in some PiSZ made matching imperfect
also. Further studies of decline in PiSZ patients are therefore
indicated.
Despite apparently similar lung function decline, subsequent
survival was better in PiSZ compared with PiZZ. There are several
possible reasons for these apparently inconsistent results. First,
declining lung function may not be a good predictor of survival;
we have recently shown that declining CT densitometry may be a
better measure.29 Alternatively, it may be that neither statistical
adjustments nor matching were capable of fully compensating for
baseline differences, such that better survival reﬂects their higher
starting point. One factor unlikely to have inﬂuenced the result is
comorbidity, which did not differ between PiSZ and ZZ patients.
Survival was worse in usual COPD than PiSZ patients, probably
due to higher comorbidity burden attendant on greater smoke
exposure, although we had insufﬁcient data to test this hypothesis.
The proportion of patients surviving 5 years was about 70% in
usual COPD and between 90% and 95% in both PiSZ and ZZ
individuals (ﬁgure 4). Since our AATD cohort is a national centre,
and many patients travel some distance to be seen, there may be a
survivor bias, which could have inﬂated the difference seen
between PiSZ and MM. If present, it would have affected PiSZ
and ZZ patients equally, hence their comparative survival result is
more robust.
Strengths and limitations
The main strengths of our study are the large number of AATD
patients, depth of clinical phenotyping and length of follow-up.
Ideally we would have compared emphysema zone and lung
function decline between PiSZ and MM, as we did for PiSZ
versus ZZ, but were limited by lack of data. However, its utility
for clinical management would be small since optimal manage-
ment of COPD should occur in both usual COPD and COPD
due to PiSZ AATD. The main difference would emerge if aug-
mentation were available, for which the more informative longi-
tudinal PiSZ comparison is with PiZZ patients. Further work to
clarify whether differences in neutrophil function occur
between PiSZ and MM patients, as they do between PiZZ and
MM,30 whether NE activity differs31 32 between groups and the
utility of augmentation in PiSZ patients may be valuable
follow-up studies.
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